GSK (NYSE:GSK) Lowered to “Neutral” Rating by Guggenheim

GSK (NYSE:GSK) was downgraded by Guggenheim from a “buy” rating to a “neutral” rating in a research report issued on Thursday, MarketBeat reports.

A number of other research firms also recently commented on GSK. Barclays raised GSK to a “hold” rating in a report on Tuesday, August 27th. UBS Group downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Finally, Argus raised GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Five investment analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

GSK Stock Performance

NYSE GSK opened at $36.87 on Thursday. The firm has a market cap of $76.41 billion, a P/E ratio of 23.94, a P/E/G ratio of 1.23 and a beta of 0.65. GSK has a 52-week low of $33.67 and a 52-week high of $45.92. The business’s 50-day moving average price is $40.66 and its 200 day moving average price is $41.02. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.99.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. GSK had a net margin of 7.97% and a return on equity of 51.23%. The company had revenue of $9.95 billion during the quarter, compared to the consensus estimate of $9.49 billion. On average, equities research analysts expect that GSK will post 4.08 earnings per share for the current year.

Insider Activity at GSK

In other GSK news, major shareholder Plc Gsk acquired 2,791,930 shares of the firm’s stock in a transaction dated Friday, September 27th. The shares were acquired at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the acquisition, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 10.00% of the company’s stock.

Institutional Investors Weigh In On GSK

Several large investors have recently made changes to their positions in GSK. Cohen Investment Advisors LLC acquired a new stake in GSK in the 2nd quarter valued at $349,000. Blair William & Co. IL grew its stake in shares of GSK by 14.9% in the first quarter. Blair William & Co. IL now owns 23,493 shares of the pharmaceutical company’s stock valued at $1,007,000 after buying an additional 3,044 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of GSK by 448.7% during the 1st quarter. SG Americas Securities LLC now owns 17,690 shares of the pharmaceutical company’s stock valued at $758,000 after buying an additional 14,466 shares during the period. Royal Fund Management LLC lifted its position in GSK by 87.0% during the 3rd quarter. Royal Fund Management LLC now owns 42,456 shares of the pharmaceutical company’s stock worth $1,737,000 after acquiring an additional 19,758 shares in the last quarter. Finally, CreativeOne Wealth LLC purchased a new position in GSK in the 1st quarter worth approximately $235,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.